Bibliography
- Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions; a systematic review of prospective observational studies. Ann Pharmacother 2008;42:1017-25
- de Leon J. Pharmacogenomics; the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 2009;34:159-72
- Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 2008;40:187-224
- Court MH. A pharmacogenomics primer. J Clin Pharmacol 2007;47:1087-103
- Taylor MR. Pharmacogenetics of the human beta-adrenergic receptors. Pharmacogenomics J 2007;7:29-37
- Small KM, Mcgraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003;43:381-411
- Bristow MR. Mechanistic and clinical rationales for using beta-blockers in heart failure. J Card Fail 2000;6:8-14
- Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7
- Muthumala A, Drenos F, Elliott PM, Humphries SE. Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. Eur J Heart Fail 2008;10:3-13
- Shin J, Johnson JA. Beta-blocker pharmacogenetics in heart failure. Heart Fail Rev 2008. [Epub ahead of print]
- Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy 2007;27:874-87
- Brodde OE. Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol Ther 2008;117:1-29
- Brodde OE. Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. Naunyn Schmiedebergs Arch Pharmacol 2007;374:361-72
- Mcnamara DM. Emerging role of pharmacogenetics in heart failure. Curr Opin Cardiol 2008;23:261-8
- Liggett SB, Wagoner LE, Craft LL, et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998;102:1534-39
- de Groote P, Lamblin N, Helbecque N et al. The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure. Eur J Heart Fail 2005;7:966-73
- Littlejohn MD, Palmer BR, Richards AM, et al. Ile164 variant of beta2-adrenoceptor does not influence outcome in heart failure but may interact with beta blocker treatment. Eur J Heart Fail 2008;10:55-9
- de Groote P, Helbecque N, Lamblin N, et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 2005;15:137-42
- Chen L, Meyers D, Javorsky G, et al. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics 2007;17:941-9
- Sehnert AJ, Daniels SE, Elashoff M, et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 2008;52:644-51
- White HL, de Boer RA, Maqbool A, et al. MERIT-HF Study Group. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 2003;5:463-8
- Rochais F, Vilardaga JP, Nikolaev VO, et al. Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest 2007;117:229-35
- Bruck H, Leineweber K, Temme T, et al. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol 2005;46:2111-5
- Wagoner LE, Craft LL, Zengel P, et al. Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J 2002;144:840-6
- Mialet Perez J, Rathz DA, Petrashevskaya NN, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003;(9):1300-5
- Terra SG, Pauly DF, Lee CR, et al. Beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 2005;77:127-37
- Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 2006;103:11288-93
- Börjesson M, Magnusson Y, Hjalmarson A, Andersson B. A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000;21:1853-8
- Magnusson Y, Levin MC, Eggertsen R, et al. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 2005;78:221-31
- Small KM, Wagoner LE, Levin AM, et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002;347:1135-42
- Lobmeyer MT, Gong Y, Terra SG, et al. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics 2007;17:277-82
- Savva J, Maqbool A, White HL, et al. Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: a MERIT-HF Substudy. J Card Fail 2009 (Article in Press doi: 10.1016/j.cardfail.2008.12.005)
- Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008;14:510-17
- Pinto YM, van Gilst WH, Kingma JH, Schunkert H. Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators. J Am Coll Cardiol 1995;25:1622-6
- Andersson B, Sylvén C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 1996;28:162-7
- Niu T, Chen X, Xu X. Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications. Drugs 2002;62:977-93
- Kitsios G, Zintzaras E. Genetic variation associated with ischemic heart failure: a huge review and meta-analysis. Am J Epidemiol 2007;166:619-33
- Calnan M, Smith GD, Sterne JA. The publication process itself was the major cause of publication bias in genetic epidemiology. J Clin Epidemiol 2006;59:1312-8
- Mcnamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001;103:1644-8
- de Groote P, Helbecque N, Lamblin N, et al. Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure. Eur J Heart Fail 2004;6:17-21
- Mcnamara DM, Holubkov R, Postava L, et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 2004;44:2019-26
- Denus S, Zakrzewski-Jakubiak M, DubéMP, et al. Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. Ann Pharmacother 2008;42:925-32
- Tiago AD, Badenhorst D, Skudicky D, et al. An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovasc Res 2002;54:584-9
- Mcnamara DM, Tam SW, Sabolinski ML, et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial. J Am Coll Cardiol 2006;48:1277-82
- Biolo A, Chao T, Duhaney TA, et al. Usefulness of the aldosterone synthase gene polymorphism C-344-T to predict cardiac remodeling in African-Americans versus non-African-Americans with chronic systolic heart failure. Am J Cardiol 2007;100:285-90
- Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-57
- Charron P, Tesson F, Poirier O, et al. Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group. Eur Heart J 1999;20:1587-91
- Taylor MR, Slavov D, Humphrey K, et al. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics 2009;19:35-43
- van der Meer P, De Boer RA, White HL, et al. The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. J Card Fail 2005;11:279-84
- de Boer RA, Pinto YM, Van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 2003;10:113-26
- Asselbergs FW, de Boer RA, Diercks GF et al. Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria? Int J Cardiol 2004;93:211-15
- Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754-62
- Burkitt EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 2005;45:969-81
- Raman SV, Sparks EA, Baker PM, et al. Midmyocardial fibrosis by cardiac magnetic resonance imaging in patients with lamin A/C cardiomyopathy: possible substrate for diastolic function. J Cardiovasc Magn Reson 2007;9:907-13
- Varghese A. Late gadolinium enhanced cardiovascular magnetic resonance in Becker muscular dystrophy. Heart 2004;90:e59
- Van Tintelen JP, Tio RA, Kerstjens-Frederikse WS, et al. Severe myocardial fibrosis caused by deletion of the 5 of the lamin A/C gene. J Am Coll Cardiol 2007;49:2430-9
- Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005;45:855-7
- Kajimoto H, Ishigaki K, Okumura K, et al. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J 2006;70:991-4
- de Boer RA, van den Berg MP, van Veldhuisen DJ. Genetics in heart failure: where are we headed? Congest Heart Fail 2006;12:329-32
- Samani NJ, Erdmann J, Hall AS, et al. WTCCC and the Cardiogenics Consortium. Genome wide association analysis of coronary artery disease. N Engl J Med 2007;357:443-53
- Schadt EE, Molony C, Chudin E, et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol 2008;6:e107
- Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008;40:189-97
- Hunter DJ, Altshuler D, Rader DJ. From Darwin's finches to canaries in the coal mine. N Engl J Med 2008;(358):2760-3
- The SEARCH Collaborative GROUP. SLCO1B1 variants and statin-induced myopathy – a genome wide study. New Engl J Med 2008;359:789-99
- FDA 2005. Guidance for industry: pharmacogenomic data submission. Available from: http://www.fda.gov/cder/guidance/6400fnl.pdf. [Last accessed 10 Oct 2008]
- Mallal S, Phillips E, Carosi G, et al. PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79
- Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009;113:784-92
- Genomas, Inc., Hartford, CT 06106. GLIM PhyzioType System: Glucose + Insulin Modulators. Available from: http://www.genomas.net. [Last accessed 25 May 2009]
- Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89
- Table of valid genomic biomarkers in the context of approved drug labels. Rockville, MD: Food and Drug Administration. Available from: http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm. [Last accessed 10 oct 2008]
- van Veldhuisen DJ, Poole-Wilson PA. The underreporting of results and possible mechanisms of ‘negative’ drug trials in patients with chronic heart failure. Int J Cardiol 2001;80:19-27
- Krumholz HM, Lee TH. Redefining quality – implications of recent clinical trials. N Engl J Med 2008;(358):2537-9
- Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17
- Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 2008;7:807-17
- van der Harst P, van der Steege G, de Boer RA, et al. Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol 2007;49:1459-64
- Stolk RP, Rosmalen JG, Postma DS, et al. Universal risk factors for multifactorial diseases: LifeLines: a three-generation population-based study. Eur J Epidemiol 2008;23:67-74
- Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008;154:1465-73
- The ENCODE, Project Consortium. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007;447:799-816
- Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature 2006;444:444-54
- Wang Y, Krishnan HR, Ghezzi A, et al. Drug-induced epigenetic changes produce drug tolerance. PLoS Biol 2007;5:e265
- The Personalized Medicine Coalition (PMC), Washington DC 20005. Available from: http://www.personalizedmedicinecoalition.org/. [Last accessed 10 Oct 2008]